

NEWS RELEASE

Niagen Bioscience to Report Third Quarter 2026 Financial Results on Wednesday, November 4, 2026

2026-10-15

LOS ANGELES--(BUSINESS WIRE)-- **Niagen Bioscience, Inc.** (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, November 4, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2026. The company will report the financial results in a press release after the close of regular stock market trading hours on Wednesday, November 4, 2026.

Investor Conference Call:

A live webcast will be held on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Standard Time (1:30 p.m. Pacific Standard Time) to discuss Niagen Bioscience's third-quarter financial results and provide a general business update.

To listen to the webcast, or to view the earnings press release and its accompanying financial exhibits, please visit the Investor Relations section of Niagen Bioscience's website at www.niagenbioscience.com.

Date: Wednesday, November 4

Time: 4:30 p.m. ET (1:30 p.m. PT)

Toll-free dial-in number: 1 (833) 461-5787

Conference ID: 198 389 474

Webcast link: **Niagen Bioscience Third Quarter Earnings Conference Call**

For additional information on Niagen Bioscience, visit **www.niagenbioscience.com**.

About Niagen Bioscience

Niagen Bioscience, Inc. (NASDAQ: NAGE) is the global authority in healthy aging and NAD⁺ (nicotinamide adenine dinucleotide) science. As a trusted pioneer of NAD⁺ discoveries, Niagen Bioscience[™] is dedicated to advancing healthspan through precision science and innovative NAD⁺-boosting solutions.

The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD⁺. A vital coenzyme found in every cell of the human body, NAD⁺ declines with age and exposure to everyday lifestyle stressors. NAD⁺ depletion is a key contributor to age-related changes in health and vitality.

Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age.

At the heart of its clinically tested product portfolio is Niagen[®] (patented nicotinamide riboside, or NR), the most efficient, well-researched, and high-quality NAD⁺ booster available. Niagen powers the Company's consumer supplement, Tru Niagen[®], the number one NAD⁺ boosting oral supplement in the United States[†] (available at **www.truniagen.com**), and Niagen[™] Plus, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products (**www.niagenplus.com**). Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. NAD Pharmaceuticals Corp., the Company's wholly owned subsidiary focused on developing therapies for accelerated aging and rare genetic diseases, is conducting research on NB4168, a small differentiated molecule.

Niagen Bioscience's robust patent portfolio protects NR and other NAD⁺ precursors. Niagen Bioscience maintains a website at **www.niagenbioscience.com**, where copies of press releases, news, and financial information are regularly published.

[†] Based on revenue per largest U.S. e-commerce marketplace (Jan. 2025 – Dec. 2025)

Niagen Bioscience Media Contact:

Kendall Knysch, Senior Director of Media Relations & Partnerships
310.405.5227

kendall.knysch@niagenbio.com

Niagen Bioscience Investor Relations Contact:

Valter Pinto, Managing Director

KCSA Strategic Communications

212.896.1254

Niagen@kcsa.com

Source: Niagen Bioscience, Inc.